What's in Infinity Pharmaceuticals, Inc.'s pipeline?

Infinity Pharmaceuticals, Inc. has 5 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Infinity Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Eli Lilly and Company, Sanofi, University of Turin, Italy.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/infinity-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Infinity Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Infinity Pharmaceuticals, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Placebo plus Docetaxel	Placebo plus Docetaxel	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Sanofi · 1 shared drug class
University of Turin, Italy · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Infinity Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Infinity Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/infinity-pharmaceuticals-inc. Accessed 2026-05-15.